Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02228681 · OUTCOME

Median Survival

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer · Source last updated 2024-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter.

What was measured

Survival is defined as the duration alive from study entry until death.

Analysis population: Eligible patients

Groups in this outcome

Everolimus and Letrozole

Everolimus 10 mg daily plus letrozole 2.5 mg PO daily in a 28 day cycle.

Tamoxifen and Medroxyprogesterone Acetate

Tamoxifen 20 mg PO bid days 1-28 plus medroxyprogesterone acetate 200 mg PO days 8-14 and 22-28 repeating in a 28 day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Everolimus and Letrozole37
Tamoxifen and Medroxyprogesterone Acetate37

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Everolimus and LetrozoleNANot reported14.2NANo upper limit or median estimate can be provided as the median survival time has not been reached.
Tamoxifen and Medroxyprogesterone Acetate16.6Not reported7.6NANo upper limit or median estimate can be provided as the median survival time has not been reached.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        No upper limit or median estimate can be provided as the median survival time has not been reached.
        group Id
        OG000
        lower Limit
        14.2
        upper Limit
        NA
        value
        NA
      2. comment
        No upper limit or median estimate can be provided as the median survival time has not been reached.
        group Id
        OG001
        lower Limit
        7.6
        upper Limit
        NA
        value
        16.6
denoms
  1. counts
    1. group Id
      OG000
      value
      37
    2. group Id
      OG001
      value
      37
    units
    Participants
description
Survival is defined as the duration alive from study entry until death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Everolimus 10 mg daily plus letrozole 2.5 mg PO daily in a 28 day cycle.
    id
    OG000
    title
    Everolimus and Letrozole
  2. description
    Tamoxifen 20 mg PO bid days 1-28 plus medroxyprogesterone acetate 200 mg PO days 8-14 and 22-28 repeating in a 28 day cycle.
    id
    OG001
    title
    Tamoxifen and Medroxyprogesterone Acetate
param Type
MEDIAN
population Description
Eligible patients
reporting Status
POSTED
time Frame
Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter.
title
Median Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice